Chemotherapy-related myelosuppression
Conditions
Interventions
Observation group:None
Sponsors
The First Affiliated Hospital of Xinxiang Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.The confirmed malignant tumor is one of the non-small cell lung cancer/small cell lung cancer/breast cancer/gastric cancer/esophageal cancer/colorectal cancer/gynecological malignancy (ovarian cancer, cervical cancer, endometrial cancer). 2.The chemotherapy regimen received for the most recent chemotherapy should be one of the following Cancer chemotherapy regimen Non-small cell lung cancer TP scheme NP scheme DP scheme EP scheme GP scheme AP scheme Docetaxel/pemetrexed monotherapy Gemcitabine monotherapy Tigio monotherapy ADCs Other monotherapy or combination regimens containing platinum or taxane drugs Drug regimens that combine the above chemotherapy regimens (e.g., immunosuppressants, targeted therapy drugs, etc.) Small cell lung cancer with etoposide-containing combination regimens Platinum-containing combination regimens (except etoposide) Monotherapy or combination regimen containing topotecan, gemcitabine, paclitaxel Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.) Breast cancer ddEC sequential T regimen Anthracyclines and taxanes: TAC, TE, EC-T, ddEC-T, FEC-T regimens Combined taxane protocols: TP, AP, TC, Anthracycline combination regimen: EC, FEC Taxane monotherapy Yew combined with platinum Other platinum-containing regimens: NP, GP ADC drugs Microtubule inhibitors: NVB, taxanes (nab-paclitaxel, paclitaxel liposome, docetaxel), eutidrone, eribulin Microtubule inhibitors in combination with capecitabine Anthracycline monotherapy Drug regimens that combine the above chemotherapy (e.g., targeted therapy drugs, etc.) Gastric cancer SOX protocol XELOX scheme FOLFOX protocol DCF scheme ADCs Other monotherapy or combination regimens containing platinum or taxanes or fluorouracil Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.) Esophageal cancer taxane + platinum regimen CF protocol DCF scheme FOLFOX protocol XELOX scheme FLOT scheme FOLFIRI PROTOCOL ECF protocol ECX scheme EOF scheme EOX protocol Other monotherapy or combination regimens containing platinum or taxane or fluorouracil Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.) COLORECTAL CANCER FOLFOXIRI FOLFOX FOLFIRI XELOX Other monotherapy or combination regimens containing platinum or fluorouracil or raltitrexed Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.) Gynecologic malignancies: platinum + taxane or its combination regimen Monotherapy or combination chemotherapy containing docetaxel/gemcitabine/topotecan/irinotecan Regimens (except platinum + taxanes) Other monotherapy or combination chemotherapy regimens containing platinum, taxanes, or anthracyclines; 3.Understand and sign the informed consent form; 4.The relevant diagnosis and treatment information involved in the study is complete: only patients with at least 1-2 test results after 1 week after chemotherapy can be included; 5.Patients who have required chemotherapy within the last 3 months and should continue chemotherapy in the future;
Exclusion criteria
Exclusion criteria: 1.Patients with concurrent chemoradiotherapy, b. Patients with sequential chemoradiotherapy, and the irradiation site is flat bone, sternum, and pelvis; 2.Patients with active bleeding before or during treatment; 3.If the patient has received targeted drugs such as CDK4/6 inhibitors or chidaaniline in front-line treatment, which have a great impact on the blood phase, the drug should be stopped for at least half a month before it can be included; 4.Patients who, in the opinion of other physicians, would cause non-chemotherapy-related myelosuppression;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the current status of chemotherapy-related bone marrow suppression and clinical management of cancer in the county; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of thrombocytopenia during chemotherapy treatment and the rate of primary and secondary prophylaxis;The incidence rate of neutropenia during chemotherapy treatment and the rates of primary and secondary preventive treatments;Neutropenia treatment rate and economic burden during chemotherapy treatment; | — |
Countries
China
Contacts
Public ContactYinghua Ji
The First Affiliated Hospital of Xinxiang Medical University
Outcome results
None listed